Boston Life Sciences Broadens Prominent Position in Development of Diagnostic Agents for Parkinson's Disease.BOSTON--(BUSINESS WIRE)--Dec. 2, 1998--Boston Life Sciences Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BLSI BLSI Boston Life Sciences, Inc. ) whose compound, Altropane (TM) is the only diagnostic agent for Parkinson's Disease currently in active advanced human clinical trials, announced that it has initiated a preclinical development program for a newly-synthesized "second generation" technetium-based compound (designated O-1506). This compound differs from Altropane in structure and in the advantageous substitution of technetium technetium (tĕknē`shēəm) [Gr. technetos=artificial], artificially produced radioactive chemical element; symbol Tc; at. no. 43; mass no. of most stable isotope 98; m.p. 2,200°C;; b.p. 4,877°C;; sp. gr. 11. for I123 as the radio-ligand. "In both in vitro and in vivo studies, O-1506 appears to demonstrate selectivity, binding characteristics, and brain striatal localization that look outstanding relative to all other reported technetium-based compounds in this class," stated Dr. Marc Lanser, Chief Scientific Officer of BLSI. "Even as Altropane continues to perform exceedingly well in our clinical trials, we believe that the subsequent introduction of a user-friendly, technetium-based Parkinson's diagnostic product has the potential to substantially increase the market for these agents, particularly in early detection of the disease. The ability to eventually follow Altropane to market, if approved, with a second-generation technetium product would, in our view, give BLSI a long-term competitive advantage in this rapidly emerging diagnostic area. While our priority is to continue to focus on commercialization of Altropane in the U.S., we plan to develop O-1506 worldwide because of potentially simpler manufacturing and distribution considerations," added Dr. Lanser. The foregoing contains forward-looking statements with regard to product development timelines and regulatory filings, which may not be realized due to the uncertainties inherent in the research and development process. BLSI is developing novel treatments for cancer, autoimmune disease, and central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . In addition to Altropane and O-1506, products awaiting FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. review, in clinical trials or in preclinical development by BLSI include THERAFECTIN for the treatment of Rheumatoid Arthritis; AFI for the potential treatment of stroke and spinal cord injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. ; Troponin troponin /tro·po·nin/ (tro´po-nin) a complex of muscle proteins which, when combined with Ca2+, influence tropomyosin to initiate contraction. tro·po·nin n. , an anti-angiogenic treatment for cancer and eye diseases, and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion